BFM
HZNP

Boothbay Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Boothbay Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,600
Closed -$718K – 2823
2022
Q3 		$718K Sell
11,600
-62,900
-84% -$4.4M 0.02% 1052
2022
Q2 		$5.94M Buy
74,500
+56,700
+319% +$5.37M 0.16% 135
2022
Q1 		$1.87M Sell
17,800
-91,000
-84% -$8.87M 0.04% 605
2021
Q4 		$11.7M Buy
108,800
+66,600
+158% +$7.27M 0.28% 58
2021
Q3 		$4.62M Buy
42,200
+14,000
+50% +$1.45M 0.13% 185
2021
Q2 		$2.64M Buy
28,200
+27,522
+4,059% +$2.53M 0.08% 290
2021
Q1 		$6.24M Sell
678
-366
-35% -$30.9K 0.23% 77
2020
Q4 		$7.64M Buy
1,044
+625
+149% +$46.5K 0.28% 49
2020
Q3 		$3.25M Buy
419
+221
+112% +$15.2K 0.2% 114
2020
Q2 		$1.1M Buy
+198
New +$8.47K 0.08% 357

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boothbay Fund Management's HZNP Position: Q4 2023 in Review

Boothbay Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 69,911 shares — an estimated $8.09M sold.

Boothbay Fund Management first reported a position in HZNP in Q4 2018 and held it in 14 quarters. The position peaked at $10.5M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Boothbay Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 69,911 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.09M.
  • Boothbay Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 14 quarters.
  • Boothbay Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.5M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.